18 July 2023
18 July 2023
Versanis’ lead asset, bimagrumab, is currently being evaluated in the Phase IIb BELIEVE clinical trial.
The companies will develop new molecules using Eleven's innovative DELiveri platform to treat cardiometabolic diseases.
The US Federal Court overturned a previous ruling in the patent infringement case against Rockefeller University.
If reclassified, all strengths of the therapeutic will only be available on prescription.
The move follows a positive decision made by the EMA earlier this year, broadening the use of Veklury to the high-risk patient group.
Scribe is eligible to receive $1.2bn in milestone payments from Sanofi.
Patent trends have been on the rise in inflammation, diabetes, and Alzheimer's disease, in line with rising drug revenues in those areas.
The transaction will be completed in the third quarter of 2023.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
